Novel psoriasis therapies and patient outcomes, part 3: Systemic medications

Meghan A. Feely, Barry L. Smith, Jeffrey M. Weinberg

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The therapeutic armamentarium for patients with psoriasis and psoriatic arthritis (PsA) has been strengthened by research affording more individualized treatment regimens with new therapeutic targets. In this article, new systemic therapies for psoriasis are discussed, including a review of the relevant clinical trials for novel therapeutics and their respective mechanisms of action, patient outcomes, and safety profiles. This article is the final installment in a 3-part series on agents in the pipeline for the management of psoriasis and PsA including topical agents, biologic treatments, and systemic therapies in phase 2 through phase 4 clinical trials. These systemic agents offer patients more targeted treatment regimens with the prospect of enhanced therapeutic efficacy and more favorable side-effect profiles with better tolerability.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
Issue number1
StatePublished - 2015


Dive into the research topics of 'Novel psoriasis therapies and patient outcomes, part 3: Systemic medications'. Together they form a unique fingerprint.

Cite this